Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) Stock Crosses Above 200-Day Moving Average - Here's What Happened

Key Points

• OACC crossed above its 200-day moving average of $10.70, reaching $10.72 before last trading at $10.71 on volume of 1,940 shares.
• Weiss Ratings upgraded the stock from “sell (d+)” to “hold (c-),” while the sole analyst rating and overall consensus remain Hold.
• Rangeley Capital increased its stake by 52.8% in the first quarter to 61,188 shares, representing a 0.25% ownership position valued at approximately $647,000.

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $10.70 and traded as high as $10.72. Oaktree Acquisition Corp. III Life Sciences shares last traded at $10.71, with a volume of 1,940 shares.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded Oaktree Acquisition Corp. III Life Sciences from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Friday, October 2nd. One analyst has rated the stock with a Hold rating. According to data from MarketBeat, Oaktree Acquisition Corp. III Life Sciences presently has a consensus rating of "Hold".

Oaktree Acquisition Corp. III Life Sciences Stock Up 0.2%

The business's 50 day moving average is $10.76 and its 200-day moving average is $10.70.

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC - Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported $0.07 earnings per share for the quarter.

Institutional Trading of Oaktree Acquisition Corp. III Life Sciences

A hedge fund recently raised its stake in Oaktree Acquisition Corp. III Life Sciences stock. Rangeley Capital LLC increased its position in shares of Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC - Free Report) by 52.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 61,188 shares of the company's stock after purchasing an additional 21,156 shares during the period. Rangeley Capital LLC owned 0.25% of Oaktree Acquisition Corp. III Life Sciences worth $647,000 at the end of the most recent quarter.

Oaktree Acquisition Corp. III Life Sciences Company Profile

Oaktree Acquisition Corp. III Life Sciences is a special purpose acquisition company (SPAC) formed to identify and complete a business combination with a company in the life sciences sector. The company does not operate as a traditional life sciences manufacturer or service provider and does not currently market its own products.

Its stated focus includes potential merger or acquisition opportunities involving pharmaceutical, biotechnology, medical device, diagnostics, and other healthcare-related businesses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.